In patients with unresectable HCC, outcomes with atezolizumab plus bevacizumab are not improved by the addition of low-dose ipilimumab. Presented at #ESMO25 by Dr Philippe Merle of @hospicescivilslyon.bsky.social. #gicsm #hccsm #esmo2025

shorturl.at/MVYsh